Association between glucagon-like peptide-1 receptor agonist use and progression of monoclonal gammopathy of uncertain significance to multiple myeloma among patients with diabetes
For patients with diabetes and MGUS, GLP-1 receptor agonist use is associated with a 55% reduction in risk of progression from MGUS to multiple myeloma compared with no use.
Authors
- Feng Gao (ORCID: https://orcid.org/0000-0002-1425-1623)
- Su‐Hsin Chang (ORCID: https://orcid.org/0000-0001-5872-9556)
- Lawrence Liu (ORCID: https://orcid.org/0000-0001-8559-7739)
- Graham A. Colditz (ORCID: https://orcid.org/0000-0002-7307-0291)
- Kristen M. Sanfilippo (ORCID: https://orcid.org/0000-0002-0433-7845)
- Murali Janakiram (ORCID: https://orcid.org/0000-0001-9323-8007)
- Martin William Schoen (ORCID: https://orcid.org/0000-0001-6388-5553)
- Kenneth R. Carson (ORCID: https://orcid.org/0000-0001-7471-9542)
- Nikhil Grandhi
- Mei Wang (ORCID: https://orcid.org/0000-0002-3560-9460)
- Theodore Thomas
Institutions
- Northwestern University (US)
- Washington University in St. Louis (US)
- St. Louis VA Medical Center (US)
- City of Hope (US)
- Saint Louis University (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1093/jncics/pkae095
- Citations
- 9
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.10